These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15548126)

  • 21. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.
    Du Pan SM; Dehler S; Ciurea A; Ziswiler HR; Gabay C; Finckh A;
    Arthritis Rheum; 2009 May; 61(5):560-8. PubMed ID: 19405000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.
    Nuijten MJ; Engelfriet P; Duijn K; Bruijn G; Wierz D; Koopmanschap M
    Pharmacoeconomics; 2001; 19(10):1051-64. PubMed ID: 11735673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone.
    Wisłowska M; Jakubicz D
    Rheumatol Int; 2007 May; 27(7):641-7. PubMed ID: 17235556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
    Buch MH; Bingham SJ; Bejarano V; Bryer D; White J; Reece R; Quinn M; Emery P
    Arthritis Rheum; 2007 Apr; 57(3):448-53. PubMed ID: 17394231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduction of biological agent dose in rheumatic diseases: descriptive analysis of 153 patients in clinical practice conditions.
    Inciarte-Mundo J; Hernández MV; Rosario V; Ruiz-Esquide V; Cabrera-Villalba S; Ramírez J; Cañete JD; Sanmartí R
    Reumatol Clin; 2014; 10(1):10-6. PubMed ID: 23876791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence on effectiveness of early treatment with anti-TNF therapy in rheumatoid arthritis.
    Escudero-Vilaplana V; Ramírez-Herraiz E; Trovato-López N; Alañón-Plaza E; Bellini MJ; Herranz-Alonso A; Bellón-Cano JM; Morell-Baladrón A; Sanjurjo-Sáez M
    J Pharm Pharm Sci; 2012; 15(3):355-60. PubMed ID: 22974785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of treatment intensification with adalimumab, etanercept and infliximab in rheumatoid arthritis: a systematic review of cohort studies with focus on dose.
    Eng G; Stoltenberg MB; Szkudlarek M; Bouchelouche PN; Christensen R; Bliddal H; Marie Bartels E
    Semin Arthritis Rheum; 2013 Oct; 43(2):144-51. PubMed ID: 23838092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Symmons DP; Watson KD; Silman AJ;
    Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab.
    Neovius M; Arkema EV; Olsson H; Eriksson JK; Kristensen LE; Simard JF; Askling J;
    Ann Rheum Dis; 2015 Feb; 74(2):354-60. PubMed ID: 24285495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.
    Smolen JS; Kay J; Matteson EL; Landewé R; Hsia EC; Xu S; Zhou Y; Doyle MK
    Ann Rheum Dis; 2014 Oct; 73(10):1811-8. PubMed ID: 23897769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review.
    Ariza-Ariza R; Navarro-Sarabia F; Hernández-Cruz B; Rodríguez-Arboleya L; Navarro-Compán V; Toyos J
    Rheumatology (Oxford); 2007 Mar; 46(3):529-32. PubMed ID: 17012439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure.
    Wakabayashi H; Hasegawa M; Nishioka Y; Minami Y; Nishioka K; Sudo A
    Clin Rheumatol; 2013 Feb; 32(2):253-9. PubMed ID: 23179002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Etanercept response in patients with rheumatoid arthritis after secondary loss of efficacy of infliximab.
    Matsuno H
    Mod Rheumatol; 2010 Dec; 20(6):561-5. PubMed ID: 20552246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment patterns of anti-TNF agents in Italy: an observational study.
    Punzi L; Matucci Cerinic M; Cantini F; Bagnato G; Fiocco U; Ferri C; Bombardieri S
    Reumatismo; 2011 Mar; 63(1):18-28. PubMed ID: 21509346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study.
    Schabert VF; Bruce B; Ferrufino CF; Globe DR; Harrison DJ; Lingala B; Fries JF
    Curr Med Res Opin; 2012 Apr; 28(4):569-80. PubMed ID: 22236091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [TNF inhibitors for treatment of rheumatoid arthritis].
    Otomo K; Koike T
    Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2405-12. PubMed ID: 19149036
    [No Abstract]   [Full Text] [Related]  

  • 39. Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > or =65 years with rheumatoid arthritis.
    Weycker D; Yu EB; Woolley JM; Oster G
    Clin Ther; 2005 May; 27(5):646-56. PubMed ID: 15978314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice.
    Blom M; Kievit W; Kuper HH; Jansen TL; Visser H; den Broeder AA; Brus HL; van de Laar MA; van Riel PL
    Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1335-41. PubMed ID: 20506128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.